• ホーム
  • 検索結果
  • Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2.

Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2.

International journal of oncology (2014-05-09)
Min Wang, Dong Ren, Wei Guo, Zeyu Wang, Shuai Huang, Hong Du, Libing Song, Xinsheng Peng
要旨

Evidence in literature has demonstrated that some microRNAs (miRNAs) play a pivotal role in most solid tumor metastasis. Previous studies have showed that miR-100 is downregulated in human prostate cancer tissue compared to normal prostate and also significantly decreased in bone metastatic prostate cancer samples compared with primary prostate cancer. Argonaute 2 (AGO2) is the core effector protein of the miRNA-induced silencing complex and overexpression of AGO2 might enhance tumor metastasis. However, it is unknown whether and how miR-100 and AGO2 regulates metastasis of prostate cancer. Here, we report that miR-100 negatively regulated migration, invasion, epithelial-mesenchymal transition (EMT), colony formation, spheroid formation and expression of the stemness factors c-Myc, Oct4 and Klf4 in PC-3 and DU145 cells. Furthermore, miR-100 expression was negatively correlated with bone metastasis of prostate cancer patients. Notably, luciferase assay showed that AGO2 was a direct target of miR-100. Downregulation of AGO2 repressed migration, invasion, EMT and stemness of prostate cancer cells, and reversed the effects seen with miR-100 downregulation. Downregulation of AGO2 enhanced expression of miR-34a and miR-125b which can suppress migration, invasion, EMT and stemness of cancer cells. Taken together, our findings indicate that loss of miR-100 promotes the metastatic ability of prostate cancer cells at least partially by upregulating AGO2 expression through modulating migration, invasion, EMT and stemness of cancer cells, and suggest that miR-100/AGO2 may play an important role in regulating the metastasis of prostate cancer and is a potential target of prevention and therapy.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
モノクロナール抗フィブロネクチン マウス宿主抗体, clone FN-15, ascites fluid
Sigma-Aldrich
モノクロナール抗フィブロネクチン マウス宿主抗体, clone IST-4, ascites fluid
Sigma-Aldrich
モノクロナール抗フィブロネクチン マウス宿主抗体, clone IST-3, ascites fluid
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 3F4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
抗OCT3抗体 ウサギ宿主抗体, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, clone 67A4, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-FN1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
モノクロナール抗Cdh1, clone DCS-266, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1170, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1172, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-CDH1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1180, purified immunoglobulin, buffered aqueous glycerol solution